# A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

> **NCT03494231** · PHASE1 · TERMINATED · sponsor: **Henlix, Inc** · enrollment: 5 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** HLX06

## Key facts

- **NCT ID:** NCT03494231
- **Lead sponsor:** Henlix, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-22
- **Primary completion:** 2019-05-17
- **Final completion:** 2019-05-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03494231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03494231, "A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03494231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*